Therapies
Friday, August 10th, 2012
American Heart Association: August 7, 2012 Background and Purpose—Endothelin is considered to be a key mediator of vasospasm after subarachnoid hemorrhage. A meta-analysis of randomized trials on the effectiveness of endothelin receptor antagonists in subarachnoid hemorrhage has been published previously, but since then new major trials have been published. We present the results of a systematic […]
Therapies
Friday, August 10th, 2012
Biomedcentral.com: Published: 26 July 2012 An observational study to examine whether thrombolytic therapy in stroke patients realizes better quality of life outcomes compared to patients without thrombolytic therapy one year after stroke. We also examined whether daily functioning, mental functioning and activities improved after thrombolytic treatment. Subjects: A total of 88 stroke patients were interviewed at […]
Therapies
Friday, August 10th, 2012
Journal of Cerebral Blood Flow & Metabolism: 7/18/12 Recombinant tissue plasminogen activator (tPA) is the only approved medication in acute ischemic stroke. However, <20% of all stroke patients receive tPA (Weimar et al, 2006), a situation mainly owed to the narrow treatment time window of 4.5 hours. Another significant limitation of tPA is bleeding-related adverse events. Moreover, as […]
Atrial Fibrillation
Friday, August 10th, 2012
American College of Cardiology Foundation: August 7, 2012 Since the seminal paper by Haissaguerre et al. (1) describing the importance of pulmonary vein (PV) triggers in the initiation of paroxysmal atrial fibrillation (AF), PV isolation has become the cornerstone of catheter ablation for AF, demonstrating acceptable results (2). By contrast, reported long-term success rates after catheter […]
Atrial Fibrillation
Friday, August 10th, 2012
American Heart Association: August 7, 2012 Background and Purpose—Atrial fibrillation (AF) is an independent risk factor for stroke. Recent studies have demonstrated that the CHA2DS2-VASc scheme is useful for selecting patients who are truly at low risk. The goal of the present study was to compare the risk of ischemic stroke among AF patients with a […]
Atrial Fibrillation
Friday, August 10th, 2012
American Heart Association: August 6, 2012 Background—Uncertainty remains over optimal antithrombotic treatment of patients with atrial fibrillation (AF) presenting with myocardial infarction (MI) and/or undergoing coronary intervention (PCI). We investigated the risk and time-frame for bleeding following MI/PCI in AF patients according to antithrombotic treatment. Methods and Results—Patients with AF and admitted with MI or for […]
Atrial Fibrillation
Friday, August 10th, 2012
American Heart Association: Thursday, Aug. 2, 2012 Atrial fibrillation (AF) is an important cause of stroke and the likely cause of ischemic stroke in 20% of men and 30% of women.1 Cardiac embolism is more likely to result in a major cerebral vessel occlusion, hence the strokes associated with AF more commonly result in severe disability or […]
Atrial Fibrillation
Friday, August 10th, 2012
Nature Reviews Nephrology (24 July 2012) Atrial fibrillation is an important cause of preventable, disabling stroke and is particularly frequent in patients with chronic kidney disease (CKD). Stage 3 CKD is an independent risk factor for stroke in patients with atrial fibrillation. Warfarin anticoagulation is efficacious for stroke prevention in atrial fibrillation patients with stage 3 […]
Guidelines
Friday, August 10th, 2012
American Heart Association: Aug 2, 2012 Atrial fibrillation (AF) is an important cause of stroke and the likely cause of ischemic stroke in 20% of men and 30% of women.1 Cardiac embolism is more likely to result in a major cerebral vessel occlusion, hence the strokes associated with AF more commonly result in severe disability or […]
Guidelines
Tuesday, August 7th, 2012
Content.onlinejacc.org: 7/31/12 The most recent American College of Cardiology Foundation/American Heart Association/Heart Rhythm Society (ACCF/AHA/HRS) guidelines related to pacemaker implantation were published as part of a larger document related to device-based therapy (1). While this document provides some comments on pacemaker mode selection and algorithms to guide selection, it does not provide specific recommendations regarding […]
